GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome

Overview

Journal Int J Endocrinol Metab

Publisher Brieflands

Specialty Endocrinology

Date 2013 Jul 5

PMID 23825982

Citations 5

Authors

Pilar Alama

Jose Bellver

Carmen Vidal

Juan Giles

Affiliations

Soon will be listed here.

Abstract

The GnRH analogue (agonist and antagonist GnRH) changed ovarian stimulation. On the one hand, it improved chances of pregnancy to obtain more oocytes and better embryos. This leads to an ovarian hyper-response, which can be complicated by the ovarian hyperstimulation syndrome (OHSS). On the other hand, the GnRH analogue can prevent the incidence of OHSS: GnRH antagonist protocols, GnRH agonist for triggering final oocyte maturation, either together or separately, coasting, and the GnRH analogue may prove useful for avoiding OHSS in high-risk patients. We review these topics in this article.

Citing Articles

Stringent Regulations of Oocyte Donation Among Jewish Women in Israel: Characteristics and Outcomes of the National Oocyte Donation Program in One Central IVF Unit.

Preisler L, Samara N, Kalma Y, Arad T, Groutz A, Azem F J Relig Health. 2024; 64(1):124-147.

PMID: 39652246 PMC: 11845420. DOI: 10.1007/s10943-024-02200-7.

Comparison of pregnancy outcomes in women with normal ovarian response to the gonadotropin-releasing hormone agonist protocol using different trigger methods: a single-center retrospective cohort study based on propensity score matching.

Guo D, Pang C, Wang K Arch Gynecol Obstet. 2024; 309(5):2153-2165.

PMID: 38494512 DOI: 10.1007/s00404-024-07404-6.

Impact of GnRH agonist and GnRH antagonist on GDF9 and BMP15 expression in mouse ovaries and oocyte development.

Guo X, Huang Y, Ou Y, Chen X, Xian Y, Chen S Anim Reprod. 2023; 20(4):e20230040.

PMID: 38074942 PMC: 10707535. DOI: 10.1590/1984-3143-AR2023-0040.

Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A....

Santi D, Casarini L, Alviggi C, Simoni M Front Endocrinol (Lausanne). 2017; 8:114.

PMID: 28620352 PMC: 5451514. DOI: 10.3389/fendo.2017.00114.

Comparison of different stimulation protocols used in in vitro fertilization: a review.

Shrestha D, La X, Feng H Ann Transl Med. 2015; 3(10):137.

PMID: 26207230 PMC: 4486909. DOI: 10.3978/j.issn.2305-5839.2015.04.09.

References

Bellver J, Munoz E, Ballesteros A, Soares S, Bosch E, Simon C . Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod. 2003; 18(11):2283-8. DOI: 10.1093/humrep/deg451. View

Orvieto R . Can we eliminate severe ovarian hyperstimulation syndrome?. Hum Reprod. 2004; 20(2):320-2. DOI: 10.1093/humrep/deh613. View

Papanikolaou E, Bourgain C, Kolibianakis E, Tournaye H, Devroey P . Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Hum Reprod. 2005; 20(6):1541-7. DOI: 10.1093/humrep/deh793. View

Kolibianakis E, Schultze-Mosgau A, Schroer A, VAN Steirteghem A, Devroey P, Diedrich K . A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005; 20(10):2887-92. DOI: 10.1093/humrep/dei150. View

Abramov Y, Elchalal U, Schenker J . Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril. 1998; 70(6):1070-6. DOI: 10.1016/s0015-0282(98)00350-1. View

. Ovarian hyperstimulation syndrome. Fertil Steril. 2008; 90(5 Suppl):S188-93. DOI: 10.1016/j.fertnstert.2008.08.034. View

Elizur S, Tulandi T . Drugs in infertility and fetal safety. Fertil Steril. 2008; 89(6):1595-602. DOI: 10.1016/j.fertnstert.2008.02.092. View

Griesinger G, von Otte S, Schroer A, Ludwig A, Diedrich K, Al-Hasani S . Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod. 2007; 22(5):1348-52. DOI: 10.1093/humrep/dem006. View

Galindo A, Bodri D, Guillen J, Colodron M, Vernaeve V, Coll O . Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009; 25(1):60-6. DOI: 10.1080/09513590802404013. View

10.

Walz A, Keck C, Weber H, Kissel C, Pietrowski D . Effects of luteinizing hormone and human chorionic gonadotropin on corpus luteum cells in a spheroid cell culture system. Mol Reprod Dev. 2005; 72(1):98-104. DOI: 10.1002/mrd.20325. View

11.

Balaban B, Urman B, Ata B, Isiklar A, Larman M, Hamilton R . A randomized controlled study of human Day 3 embryo cryopreservation by slow freezing or vitrification: vitrification is associated with higher survival, metabolism and blastocyst formation. Hum Reprod. 2008; 23(9):1976-82. DOI: 10.1093/humrep/den222. View

12.

Mansour R, Aboulghar M, Serour G, Amin Y, Abou-Setta A . Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod. 2005; 20(11):3167-72. DOI: 10.1093/humrep/dei180. View

13.

Prapas Y, Panagiotidis I, Kalogiannidis I, Gjata E, Papatheodorou A, Prapa S . Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study. Reprod Biomed Online. 2010; 21(2):159-65. DOI: 10.1016/j.rbmo.2010.04.030. View

14.

Aboulghar M . Agonist and antagonist coast. Fertil Steril. 2012; 97(3):523-6. DOI: 10.1016/j.fertnstert.2012.01.094. View

15.

Bellver J, Ferrando M, Garrido N, Pellicer A . Blood group and ovarian hyperstimulation syndrome. Fertil Steril. 2009; 93(1):270-1. DOI: 10.1016/j.fertnstert.2009.07.983. View

16.

Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E . A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996; 15(2):290-98. PMC: 449944. View

17.

Bates D, Harper S . Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol. 2003; 39(4-5):225-37. DOI: 10.1016/s1537-1891(03)00011-9. View

18.

Alvarez C, Alonso-Muriel I, Garcia G, Crespo J, Bellver J, Simon C . Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod. 2007; 22(12):3210-4. DOI: 10.1093/humrep/dem315. View

19.

Al-Inany H, Abou-Setta A, Aboulghar M . Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006; (3):CD001750. DOI: 10.1002/14651858.CD001750.pub2. View

20.

Rollene N, Amols M, Hudson S, Coddington C . Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril. 2009; 92(3):1169.e15-1169.e17. DOI: 10.1016/j.fertnstert.2009.05.062. View